Limits...
Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.

Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, Kikuchi S, Watanabe M - Cancer Sci. (2014)

Bottom Line: Analysis using a multivariate proportional hazard model identified the most significant RTKs that represented independent prognostic relevance.Significant prognostic relevance was similarly confirmed for IGF-1R (P = 0.014), and EGFR (P = 0.030), but not for EphA2 or HER2 expression.Of the 53 patients who recurred, 40 patients (75.5%) were HER3-positive.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining of receptor tyrosine kinase (RTK) expression in the 13th JGCA stage II/III gastric cancer (×400). (a) EGFR immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+ and IHC 1+. (b) HER2 immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+, IHC 1+, and IHC 0. (c) HER3 immunohistochemical staining included strong staining (IHC 2+). Other lower staining levels detected were IHC 1+, and IHC 0. (d) IGF-1R immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels. (d) EphA2 immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317956&req=5

fig01: Immunohistochemical staining of receptor tyrosine kinase (RTK) expression in the 13th JGCA stage II/III gastric cancer (×400). (a) EGFR immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+ and IHC 1+. (b) HER2 immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+, IHC 1+, and IHC 0. (c) HER3 immunohistochemical staining included strong staining (IHC 2+). Other lower staining levels detected were IHC 1+, and IHC 0. (d) IGF-1R immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels. (d) EphA2 immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels.

Mentions: Immunohistochemical staining of the RTK family members EGFR, HER2, HER3, IGF-1R, and EphA2 in stage II/III advanced gastric cancer was performed. This analysis indicated that these RTKs were predominantly expressed by cancer cells in the gastric cancer tissues. Very strong immunohistochemical staining (IHC 3+) of EGFR and HER2 was observed in some tissues, while 3+ staining of HER3, IGF-1R, or EphA2 was not detected. The breakdown of immunohistochemical grade of RTK expression in the total 167 patients was as follows: EGFR; IHC 1+ (n = 62; 37.1%), IHC 2+ (n = 57; 34.1%), and IHC 3+ (n = 48; 28.8%) (Fig. 1a). HER2; IHC 0 (n = 96; 57.5%), IHC 1+ (n = 52; 31.1%), IHC 2+ (n = 8; 4.8%), and IHC 3+ (n = 11; 6.6%) (Fig. 1b). HER3; IHC 0 (n = 69; 41.3%), IHC 1+ (n = 68; 40.7%), and IHC 2+ (n = 30; 18.0%) (Fig. 1c). IGF-1R; IHC 0 (n = 79; 47.3%), IHC 1+ (n = 65; 38.9%), and IHC 2+ (n = 23; 13.8%) (Fig. 1d). EphA2; IHC 0 (n = 101; 60.5%), IHC 1+ (n = 54; 32.3%), and IHC 2+ (n = 12; 7.2%) (Fig. 1e).


Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.

Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, Kikuchi S, Watanabe M - Cancer Sci. (2014)

Immunohistochemical staining of receptor tyrosine kinase (RTK) expression in the 13th JGCA stage II/III gastric cancer (×400). (a) EGFR immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+ and IHC 1+. (b) HER2 immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+, IHC 1+, and IHC 0. (c) HER3 immunohistochemical staining included strong staining (IHC 2+). Other lower staining levels detected were IHC 1+, and IHC 0. (d) IGF-1R immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels. (d) EphA2 immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317956&req=5

fig01: Immunohistochemical staining of receptor tyrosine kinase (RTK) expression in the 13th JGCA stage II/III gastric cancer (×400). (a) EGFR immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+ and IHC 1+. (b) HER2 immunohistochemical staining included very strong staining (IHC 3+). Other lower staining levels detected were IHC 2+, IHC 1+, and IHC 0. (c) HER3 immunohistochemical staining included strong staining (IHC 2+). Other lower staining levels detected were IHC 1+, and IHC 0. (d) IGF-1R immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels. (d) EphA2 immunohistochemical staining did not include strong staining (IHC 3+), but did include IHC 2+, IHC 1+, and IHC 0 staining levels.
Mentions: Immunohistochemical staining of the RTK family members EGFR, HER2, HER3, IGF-1R, and EphA2 in stage II/III advanced gastric cancer was performed. This analysis indicated that these RTKs were predominantly expressed by cancer cells in the gastric cancer tissues. Very strong immunohistochemical staining (IHC 3+) of EGFR and HER2 was observed in some tissues, while 3+ staining of HER3, IGF-1R, or EphA2 was not detected. The breakdown of immunohistochemical grade of RTK expression in the total 167 patients was as follows: EGFR; IHC 1+ (n = 62; 37.1%), IHC 2+ (n = 57; 34.1%), and IHC 3+ (n = 48; 28.8%) (Fig. 1a). HER2; IHC 0 (n = 96; 57.5%), IHC 1+ (n = 52; 31.1%), IHC 2+ (n = 8; 4.8%), and IHC 3+ (n = 11; 6.6%) (Fig. 1b). HER3; IHC 0 (n = 69; 41.3%), IHC 1+ (n = 68; 40.7%), and IHC 2+ (n = 30; 18.0%) (Fig. 1c). IGF-1R; IHC 0 (n = 79; 47.3%), IHC 1+ (n = 65; 38.9%), and IHC 2+ (n = 23; 13.8%) (Fig. 1d). EphA2; IHC 0 (n = 101; 60.5%), IHC 1+ (n = 54; 32.3%), and IHC 2+ (n = 12; 7.2%) (Fig. 1e).

Bottom Line: Analysis using a multivariate proportional hazard model identified the most significant RTKs that represented independent prognostic relevance.Significant prognostic relevance was similarly confirmed for IGF-1R (P = 0.014), and EGFR (P = 0.030), but not for EphA2 or HER2 expression.Of the 53 patients who recurred, 40 patients (75.5%) were HER3-positive.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

Show MeSH
Related in: MedlinePlus